Investment Summary

Gilde Healthcare Invests In Vapotherm

On April 7, 2014, private equity firm Gilde Healthcare invested in medical products company Vapotherm

Investment Highlights
  • This is Gilde Healthcare’s 6th transaction in the Medical Products sector.
  • This is Gilde Healthcare’s 8th transaction in the United States.
  • This is Gilde Healthcare’s 1st transaction in New Hampshire.

Investment Summary
Date 2014-04-07
Target Vapotherm
Sector Medical Products
Investor(s) Gilde Healthcare
Deal Type Venture

Target

Vapotherm

Exeter, New Hampshire, United States
Vapotherm, Inc. is a privately held manufacturer of advanced respiratory care devices based in Exeter, New Hampshire. The company develops innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Gilde Healthcare

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1999
PE ASSETS 2.6B EUR
Size Large
Type Sector Focused
DESCRIPTION

Gilde Healthcare is a specialist private equity and venture investor focused on the healthcare sector. The Firm's buyout group targets majority investments throughout Europe (preference for Germany, the Netherlands, Belgium, Austria or Switzerland) and has a focus on healthcare providers, suppliers and service providers active in the healthcare market. The Firm's venture group looks to invest in early stage medtech, diagnostics, digital health and therapeutics companies throughout North America and Europe. Gilde Healthcare was established in 2001 and is headquartered in Utrecht, the Netherlands.

DEAL STATS #
Overall 29 of 47
Sector (Medical Products) 6 of 12
Type (Venture) 23 of 31
State (New Hampshire) 1 of 1
Country (United States) 8 of 8
Year (2014) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-02-06 uniQure

Amsterdam, Netherlands

uniQure is a gene therapy company that developed the first and only gene therapy product to receive regulatory approval in the European Union. Gene therapy is a technique for correcting defective or missing genes that cause diseases. uniQure is primarily focused on rare genetic diseases, and will also start developing gene therapies for chronic and degenerative diseases that affect larger populations. uniQure was founded in 1998 and is based in Amsterdam, the Netherlands.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-08-06 Santaris Pharma A/S

Horsholm, Denmark

Santaris Pharma A/S is developing a diverse pipeline of LNA therapeutics that influence the production or activity of select RNA targets to address diseases that are difficult-to-treat with conventional drug modalities. Santaris uses its proprietary Locked Nucleic Acid (LNA) platform and tissue-targeting expertise to pioneer next-generation antisense product candidates.

Sell $250M
Mergr

Product

Company

Legal